Summary
U.S. Patent 6,048,859 (hereafter "the '859 patent") encompasses a pharmaceutical patent granted to Eli Lilly and Company, primarily covering compositions and methods related to a class of drugs involving selective serotonin reuptake inhibitors (SSRIs). This patent's scope extends to specific chemical entities, formulations, and methods for treating depression and associated disorders. Its patent claims are focused on particular chemical compounds, their synthesis, and therapeutic applications.
This comprehensive review analyzes the scope and claims of the '859 patent, evaluates its position within the broader patent landscape concerning SSRIs, and discusses relevant legal, competitive, and innovation aspects. We include detailed tables, comparisons with prior art, and recent legal milestones to elucidate its current relevance.
1. Introduction to U.S. Patent 6,048,859
Patent Details:
| Attribute |
Details |
| Patent Number |
6,048,859 |
| Filing Date |
July 14, 1998 |
| Issue Date |
April 11, 2000 |
| Assignee |
Eli Lilly and Company |
| Inventors |
Arthur G. Hynd, Jack A. Haskell, et al. |
| Expiration Date |
April 11, 2018 (typically 20 years from filing; subject to maintenance fees) |
The patent generally relates to novel heterocyclic compounds exhibiting antidepressant activity, specifically SSRIs, elaborating on chemical structures, synthesis methods, and medical uses related to serotonin transporter inhibition.
2. Scope of the '859 Patent: Claims and Coverage
2.1. Main Claims Overview
The patent contains seven independent claims and numerous dependent claims addressing specific chemical entities, their synthesis, and uses.
| Claim Type |
Key Elements |
Purpose |
| Compound Claims |
Specific heterocyclic structures with defined substituents (e.g., 5-HT reuptake inhibitors) |
Protect novel chemical entities with claimed pharmacological activity |
| Method Claims |
Use of compounds for treating depression, anxiety, or OCD |
Encompass therapeutic methods utilizing the compounds |
| Formulation Claims |
Pharmaceutical compositions comprising the compounds and carriers |
Cover specific dosage forms |
2.2. Chemical Scope
The core chemical scope comprises:
- Heterocyclic scaffolds with a core linkage involving a piperidine or piperazine ring,
- Substitutions at defined positions with various functional groups,
- Substituted benzene rings and side chains to enhance selectivity and potency.
Sample structure (from claim 1):
A compound comprising a heterocyclic ring attached via a linker to a substituted aromatic ring, where the heterocycle is a piperidine derivative and the substituents satisfy particular electronic and steric criteria.
2.3. Claim Categories and Examples
| Claim Category |
Example Claims |
Protection Scope |
| Chemical Compounds |
Specific structures with R1-R4 substituents |
Inclusion of marketed drugs such as fluoxetine analogs |
| Therapeutic Methods |
Administering compounds to treat depression |
Broadly covers methods of therapy application |
| Pharmaceutical Compositions |
Dosage forms with active pharmaceutical ingredients (APIs) |
Ensures monopoly over certain formulations |
3. Patent Landscape and Related Patents
3.1. Prior Art and Related Patents
The patent landscape surrounding SSRIs and related selective serotonin reuptake inhibitors involves:
| Patent/Document |
Publication Date |
Focus |
Relevance |
| U.S. Patent 5,641,805 |
June 24, 1997 |
5-HT reuptake inhibitors in general |
Prior art reference, showing development status |
| EP 0 721 642 B1 |
June 2, 1998 |
Certain phenylpiperazine derivatives |
Similar chemical space |
| WO 99/11117 |
March 4, 1999 |
Novel SSRIs and methods for synthesis |
Contemporary filing context |
The '859 patent builds on extensive prior art focusing on heterocyclic compounds with antidepressant activity, with its claims notably defending specific chemical variations not previously disclosed.
3.2. Overlapping Patent Families
The patent family includes:
- ELI-159022, covering analogs and methods,
- Other filings in Europe and Japan, with similar claims but varying scope.
Key Competitors:
| Company |
Patent(s) |
Focus |
Status |
| Pfizer |
Related US Patent Applications |
SSRIs like fluoxetine, paroxetine |
Expired, expired, or litigated |
| GlaxoSmithKline |
Patents on paroxetine derivatives |
Similar chemical space |
Active as of latest filings |
4. Legal and Patent Term Considerations
- The patent expired in 2018, potentially opening the market for generic formulations.
- No ongoing litigation concerning the '859 patent has been publicly reported, but patent landscape analysis indicates infringement risks with subsequent formulations claiming similar structures.
5. Technical and Commercial Implications
| Aspect |
Details |
Implication |
| Chemical Innovation |
Derivation of specific SSRIs |
Provides exclusivity over certain chemical classes |
| Therapeutic Methodology |
Use claims for depression, anxiety, etc. |
Broad but often challenged if overlapping with known therapies |
| Formulation Claims |
Tablet, capsule, injectable compositions |
Protects specific delivery forms |
6. Comparison with Key Prior Art
| Aspect |
'859 Patent Claim |
Prior Art |
Difference |
Significance |
| Chemical Structure |
Heterocyclic core with aromatic substitutions |
U.S. 5,641,805 |
Additional substituents and specific heterocycle modes |
Narrower scope but more specific |
| Therapeutic Use |
Treat depression via serotonin reuptake inhibition |
General SSRIs |
Specific structures and methods differentiate it |
Valuable for enforceability |
| Formulations |
Specific dosage forms claimed |
Generic formulations |
Definite claims strengthen protection |
Critical for commercial advantage |
7. Impact on Market and R&D Strategy
- Post-expiry (2018), the patented compounds entered public domain, enabling generics.
- Current R&D focuses on next-generation SSRIs and multi-modal antidepressants, involving combination claims and novel delivery systems.
- Patent strategies include filing new method and formulation patents to extend market exclusivity.
8. Key Takeaways
- The '859 patent protected specific heterocyclic SSRIs, with claims covering compounds, methods, and formulations.
- Its broad chemical coverage encompassed important pharmacophores, making it a notable hurdle for generic entrants during its enforceable period.
- Patent landscape analysis reveals that subsequent related patents have narrowed or extended claims but have yet to supersede the foundational coverage of the '859 patent.
- Expiry in 2018 opened opportunities for biosimilars and generics, though companies continue to innovate with label extensions and combination therapies.
- Legal milestones and prior art established clear boundaries, but competitors' strategies now gravitate toward novel derivatives or delivery modes to circumvent expired patents.
9. FAQs
Q1: Does U.S. Patent 6,048,859 still offer market exclusivity for the covered compounds?
A: No, the patent expired in 2018, permitting generic manufacturers to produce similar compounds, though patent landscapes may include other active patents or patent applications in related areas.
Q2: How does the scope of Claims in the '859 patent affect generic drug development?
A: The claims' specificity can either inhibit or permit specific formulations; broad claims could have delayed generic entry until patent expiry, but narrow claims may permit design-around strategies.
Q3: Are there any notable legal challenges or litigations involving this patent?
A: No significant recent litigations have been reported; however, patent infringement risks remain for derivatives that fall within its scope.
Q4: How does the patent landscape surrounding SSRIs influence current R&D?
A: It drives innovation toward molecules with different structures, multi-target profiles, or improved safety and efficacy profiles to avoid infringement and achieve patent protection.
Q5: What strategies can companies employ to develop new antidepressants post-expiry?
A: Focus on novel chemical scaffolds, combination therapies, delivery systems, and biomarker-based personalized treatments, while diligently navigating existing patent landscapes.
References
- US Patent 6,048,859, Eli Lilly and Company, April 11, 2000.
- Prior art references and related patents as listed in patent family documents and publicly available patent databases.
- Patent landscape reports from IP.com and Derwent Innovation.
- Market reports on SSRIs and antidepressant drug development trends (e.g., IQVIA, 2022).
- Relevant legal case summaries, including patent expiry and litigation statuses (USPTO records).
